Priceline Launches Cyber Week 2025: Its Biggest Travel Sale of the Year with Savings Up to 99%

Travelers can score unbeatable daily deals and flash sales on hotels, flights, rental cars, cruises and vacation packages during Priceline's biggest travel savings week Priceline today announced the launch of its Cyber Week 2025 sale, the brand's largest event of the year and the best time to score unbeatable savings. As the trusted travel platform […]

UNDER ARMOUR REPORTS SECOND QUARTER FISCAL 2026 RESULTS; PROVIDES FISCAL 2026 OUTLOOK

Under Armour, Inc. (NYSE:UAA, UA) released its unaudited financial results for the second quarter of fiscal 2026, whichended on September 30, 2025. The company reports its financial performance in accordance with Generally Accepted Accounting Principles in the United States (“GAAP”). This press release includes references to “currency neutral” and “adjusted” amounts, which are non-GAAP financial

Wounded Warrior Project Provides Emergency Funding to Support Military Families

National nonprofit strengthens organizations delivering food and financial assistance to service members and families Wounded Warrior Project® (WWP) today announced $2 million in emergency support to six nonprofit organizations providing critical support to military and veteran families impacted by the government shutdown. The funding will expand access to food support and emergency financial assistance for

THE LEELA PALACES, HOTELS AND RESORTS EXPANDS ITS FOOTPRINT IN RAJASTHAN WITH THE SIGNING OF THE LEELA JAISALMER, A LUXURY DESERT RESORT AND SPA

Strengthens its presence in the state with its first Desert Resort and Spa, elevating the brand's leisure and cultural circuit in Rajasthan. The Leela Palaces, Hotels and Resorts, India's only pure play luxury hotel brand, today announced the signing of a management agreement with The Godwin Group for The Leela Jaisalmer, marking its foray into

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Company to host conference call and webcast at 8:00 a.m. EST Protalix BioTherapeutics, Inc. (NYSEAmerican: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®plant cell-based protein expression system, today announced that it will release its financial results for the quarter ended September30, 2025 and

Asia Pacific liver health leaders and Ministry of Health officials unite in Taiwan to advance hepatocellular carcinoma surveillance and management

Senior health officials, clinicians, and policy leaders from across the Asia Pacific region convened in Taipei for the hepatocellular carcinoma (HCC) Leadership & Policy Forum, hosted by the APAC Liver Disease Alliance, the Taiwan Health Promotion Administration and the Taiwan National Health Insurance Administration. The event marked a pivotal moment in regional efforts to combat

Bring Joy Home for the Holidays with Hallmark

Hallmark's festive products, movies and memorable events inspire celebration and connection all season long Holiday magic is in the air, and Hallmark is here to help make every celebration unforgettable. This season's offerings include holiday greeting cards, unique Keepsake Ornaments and gifts-including a vintage-inspired collection from Hallmark star Lacey Chabert. Fans can also enjoy new

Quarterhill Announces Q3 2025 Financial Results

Gross Margin Expansion and Positive Adjusted EBITDA Highlight Q3 Progress Quarterhill Demonstrates Strong Improvement in Profitability and Operational Execution Quarterhill Inc. (“Quarterhill” or the “Company”) (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (“ITS”) industry, announcesitsfinancial resultsforthethree and nine monthsended September 30, 2025. All financial information

Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or

Scroll to Top